Serum CCL27 predicts the response to Bacillus Calmette-Guerin immunotherapy in non-muscle-invasive bladder cancer

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–10. doi:10.3322/caac.21492.
   PubMed Web of Science ®Google Scholar
• Cambier S, Sylvester RJ, Collette L, Gontero P, Brausi MA, van Andel G, Kirkels WJ, Silva FCD, Oosterlinck W, Prescott S, et al. EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance bacillus Calmette-Guerin. Eur Urol. 2016;69(1):60–69. doi:10.1016/j.eururo.2015.06.045.
   PubMed Web of Science ®Google Scholar
• Babjuk M, Burger M, Comperat EM, Gontero P, Mostafid AH, Palou J, van Rhijn BWG, Rouprêt M, Shariat SF, Sylvester R, et al. European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ) - 2019 update. Eur Urol. 2019;76(5):639–657. doi:10.1016/j.eururo.2019.08.016.
   PubMed Web of Science ®Google Scholar
• Kamat AM, Li R, O’Donnell MA, Black PC, Roupret M, Catto JW, Comperat E, Ingersoll MA, Witjes WP, McConkey DJ, et al. Predicting response to intravesical bacillus Calmette-Guérin immunotherapy: are we there yet? a systematic review. Eur Urol. 2018;73(5):738–748. doi:10.1016/j.eururo.2017.10.003.
   PubMed Web of Science ®Google Scholar
• Pettenati C, Ingersoll MA. Mechanisms of BCG immunotherapy and its outlook for bladder cancer. Nat Rev Urol. 2018;15(10):615–625. doi:10.1038/s41585-018-0055-4.
   PubMed Web of Science ®Google Scholar
• Kamat AM, Briggman J, Urbauer DL, Svatek R, Nogueras Gonzalez GM, Anderson R, Grossman HB, Prat F, Dinney CP. Cytokine panel for response to intravesical therapy (CyPRIT): nomogram of changes in urinary cytokine levels predicts patient response to bacillus Calmette-Guérin. Eur Urol. 2016;69(2):197–200. doi:10.1016/j.eururo.2015.06.023.
   PubMed Web of Science ®Google Scholar
• Salmasi A, Elashoff DA, Guo R, Upfill-Brown A, Rosser CJ, Rose JM, Giffin LC, Gonzalez LE, Chamie K. Urinary cytokine profile to predict response to intravesical BCG with or without HS-410 therapy in patients with non-muscle-invasive bladder cancer. Cancer Epidem Biomar. 2019;28(6):1036–1044. doi:10.1158/1055-9965.EPI-18-0893.
   PubMed Web of Science ®Google Scholar
• Redelman-Sidi G, Glickman MS, Bochner BH. The mechanism of action of BCG therapy for bladder cancer-a current perspective. Nat Rev Urol. 2014;11(3):153–162. doi:10.1038/nrurol.2014.15.
   PubMed Web of Science ®Google Scholar
• Wang B, Pan WW, Yang MH, Yang WJ, He W, Chen X, Bi J, Jiang N, Huang J, Lin T, et al. Programmed death ligand-1 is associated with tumor infiltrating lymphocytes and poorer survival in urothelial cell carcinoma of the bladder. Cancer Science. 2019;110(2):489–498. doi:10.1111/cas.13887.
   PubMed Web of Science ®Google Scholar
• Wang B, Xie S, Bi J, Liu Z, Zeng H, Huang H, Xue M, He Z, Yang M, Yu H, et al. Elevated pre-existing lymphocytic infiltrates in tumour stroma predict poor prognosis in resectable urothelial carcinoma of the bladder. Histopathology. 2019;75(3):354–364. doi:10.1111/his.13807.
   PubMed Web of Science ®Google Scholar
• Baumgartner-Nielsen J, Vestergaard C, Thestrup-Pedersen K, Deleuran M, Deleuran B. Glucocorticoid-induced tumour necrosis factor receptor (GITR) and its ligand (GITRL) in atopic dermatitis. Acta Derm Venereol. 2006;86(5):393–398. doi:10.2340/00015555-0118.
   PubMed Web of Science ®Google Scholar
• Qu K, Gu J, Ye Y, Williams SB, Dinney CP, Wu X, Kamat A. High baseline levels of interleukin-8 in leukocytes and urine predict tumor recurrence in non-muscle invasive bladder cancer patients receiving bacillus Calmette–Guerin therapy: A long-term survival analysis. Oncoimmunology. 2017;6(2):e1265719. doi:10.1080/2162402X.2016.1265719.
   PubMed Web of Science ®Google Scholar
• Jallad S, Thomas P, Newport MJ, Kern F. Baseline cytokine profiles of tuberculin-specific CD4(+) T cells in non-muscle-invasive bladder cancer may predict outcomes of BCG immunotherapy. Cancer Immunol Res. 2018;6(10):1212–1219. doi:10.1158/2326-6066.Cir-18-0046.
   PubMed Web of Science ®Google Scholar
• Karnezis T, Farnsworth RH, Harris NC, Williams SP, Caesar C, Byrne DJ, Herle P, Macheda ML, Shayan R, Zhang Y-F, et al. CCL27/CCL28-CCR10 chemokine signaling mediates migration of lymphatic endothelial cells. Cancer Res. 2019;79(7):1558–1572. doi:10.1158/0008-5472.CAN-18-1858.
   PubMed Web of Science ®Google Scholar
• Simonetti O, Goteri G, Lucarini G, Filosa A, Pieramici T, Rubini C, Biagini G, Offidani A. Potential role of CCL27 and CCR10 expression in melanoma progression and immune escape. Eur J Cancer. 2006;42(8):1181–1187. doi:10.1016/j.ejca.2006.01.043.
   PubMed Web of Science ®Google Scholar
• Crispen PL, Kusmartsev S. Mechanisms of immune evasion in bladder cancer. Cancer Immunol Immunother. 2020;69(1):3–14. doi:10.1007/s00262-019-02443-4.
   PubMed Web of Science ®Google Scholar
• Martinez R, Tapia G, De Muga S, Hernandez A, Cao MG, Teixido C, Urrea V, García E, Pedreño-López S, Ibarz L, et al. Combined assessment of peritumoral Th1/Th2 polarization and peripheral immunity as a new biomarker in the prediction of BCG response in patients with high-risk NMIBC. Oncoimmunology. 2019;8(8):8. doi:10.1080/2162402x.2019.1602460.
   Web of Science ®Google Scholar
• Pichler R, Gruenbacher G, Culig Z, Brunner A, Fuchs D, Fritz J, Gander H, Rahm A, Thurnher M. Intratumoral Th2 predisposition combines with an increased Th1 functional phenotype in clinical response to intravesical BCG in bladder cancer. Cancer Immunology, Immunotherapy. 2017;66(4):427–440. doi:10.1007/s00262-016-1945-z.
   PubMed Web of Science ®Google Scholar
• Nunez-Nateras R, Castle EP, Protheroe CA, Stanton ML, Ocal TI, Ferrigni EN, Ochkur SI, Jacobsen EA, Hou Y-X, Andrews PE, et al. Predicting response to bacillus Calmette-Guérin (BCG) in patients with carcinoma in situ of the bladder. Urol Oncol. 2014;32(1):45e23–30. doi:10.1016/j.urolonc.2013.06.008.
   Web of Science ®Google Scholar
• Yuk HD, Jeong CW, Kwak C, Kim HH, Ku JH. Elevated neutrophil to lymphocyte ratio predicts poor prognosis in non-muscle invasive bladder cancer patients: initial intravesical bacillus Calmette-Guerin treatment after transurethral resection of bladder tumor setting. Front Oncol. 2018;8:642. doi:10.3389/fonc.2018.00642.
   PubMed Web of Science ®Google Scholar
• Takayama H, Nishimura K, Tsujimura A, Nakai Y, Nakayama M, Aozasa K, Okuyama A, Nonomura N. Increased infiltration of tumor associated macrophages is associated with poor prognosis of bladder carcinoma in situ after intravesical bacillus Calmette-Guerin instillation. Journal of Urology. 2009;181(4):1894–1900. doi:10.1016/j.juro.2008.11.090.
   PubMed Web of Science ®Google Scholar
• Pichler R, Fritz J, Zavadil C, Schafer G, Culig Z, Brunner A. Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical Bacillus Calmette-Guerin therapy in bladder cancer. Oncotarget. 2016;7(26):39916–39930. doi:10.18632/oncotarget.9537.
   PubMed Web of Science ®Google Scholar
• Chevalier MF, Trabanelli S, Racle J, Salome B, Cesson V, Gharbi D, Bohner P, Domingos-Pereira S, Dartiguenave F, Fritschi A-S, et al. ILC2-modulated T cell-to-MDSC balance is associated with bladder cancer recurrence. J Clin Invest. 2017;127(8):2916–2929. doi:10.1172/Jci89717.
   PubMed Web of Science ®Google Scholar
• Kates M, Matoso A, Choi W, Baras AS, Daniels MJ, Lombardo K, Brant A, Mikkilineni N, McConkey DJ, Kamat AM, et al. Adaptive immune resistance to intravesical BCG in non-muscle invasive bladder cancer: implications for prospective BCG-unresponsive trials. Clin Cancer Res. 2020;26(4):882–891. doi:10.1158/1078-0432.CCR-19-1920.
   PubMed Web of Science ®Google Scholar
• Inman BA, Sebo TJ, Frigola X, Dong H, Bergstralh EJ, Frank I, Fradet Y, Lacombe L, Kwon ED. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer. 2007;109(8):1499–1505. doi:10.1002/cncr.22588.
   PubMed Web of Science ®Google Scholar
• Miyake M, Tatsumi Y, Gotoh D, Ohnishi S, Owari T, Iida K, Ohnishi K, Hori S, Morizawa Y, Itami Y, et al. Regulatory T cells and tumor-associated macrophages in the tumor microenvironment in non-muscle invasive bladder cancer treated with intravesical bacille Calmette-Guerin: a long-term follow-up study of a Japanese cohort. Int J Mol Sci. 2017;18(10). doi:10.3390/ijms18102186
   Web of Science ®Google Scholar
• Chevalier MF, Schneider AK, Cesson V, Dartiguenave F, Lucca I, Jichlinski P, Nardelli-Haefliger D, Derré L. Conventional and PD-L1-expressing regulatory T cells are enriched during BCG therapy and may limit its efficacy. Eur Urol. 2018;74(5):540–544. doi:10.1016/j.eururo.2018.06.045.
   PubMed Web of Science ®Google Scholar
• Kagami S, Saeki H, Tsunemi Y, Nakamura K, Kuwano Y, Komine M, Nakayama T, Yoshie O, Tamaki K. CCL27-transgenic mice show enhanced contact hypers ensitivity to Th2, but not Th1 stimuli. Eur J Immunol. 2008;38(3):647–657. doi:10.1002/eji.200737685.
   PubMed Web of Science ®Google Scholar
• Facciabene A, Peng XH, Hagemann IS, Balint K, Barchetti A, Wang LP, Gimotty PA, Gilks CB, Lal P, Zhang L, et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T-reg cells. Nature. 2011;475(7355):226–U141. doi:10.1038/nature10169.
   PubMed Web of Science ®Google Scholar